Literature DB >> 2566649

Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia.

J F Deakin1, P Slater, M D Simpson, A C Gilchrist, W J Skan, M C Royston, G P Reynolds, A J Cross.   

Abstract

Glutamatergic mechanisms have been investigated in postmortem brain samples from schizophrenics and controls. D-[3H]Aspartate binding to glutamate uptake sites was used as a marker for glutamatergic neurones, and [3H]kainate binding for a subclass of postsynaptic glutamate receptors. There were highly significant increases in the binding of both ligands to membranes from orbital frontal cortex on both the left and right sides of schizophrenic brains. The changes are unlikely to be due to antemortem neuroleptic drug treatment, because no similar changes were recorded in other areas. A predicted left-sided reduction in D-[3H]aspartate binding was refuted at 5% probability, but not at 10%. Previously reported high concentrations of dopamine in left amygdala were strongly associated with low concentrations of D-[3H]aspartate binding in left polar temporal cortex in the schizophrenics. The findings are compatible with an overabundant glutamatergic innervation of orbital frontal cortex in schizophrenia. The results also suggest that schizophrenia may involve left-sided abnormalities in the relationship between temporal glutamatergic and dopaminergic projections to amygdala.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566649     DOI: 10.1111/j.1471-4159.1989.tb07257.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  40 in total

1.  Uncinate fasciculus findings in schizophrenia: a magnetic resonance diffusion tensor imaging study.

Authors:  Marek Kubicki; Carl-Fredrik Westin; Stephan E Maier; Melissa Frumin; Paul G Nestor; Dean F Salisbury; Ron Kikinis; Ferenc A Jolesz; Robert W McCarley; Martha E Shenton
Journal:  Am J Psychiatry       Date:  2002-05       Impact factor: 18.112

Review 2.  Hippocampal neurons in schizophrenia.

Authors:  S Heckers; C Konradi
Journal:  J Neural Transm (Vienna)       Date:  2002-05       Impact factor: 3.575

Review 3.  [Effect of antipsychotics on glutaminergic neural transmission in the animal model].

Authors:  A Schmitt; B May; B Müller; M Zink; D F Braus; F A Henn
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

Review 4.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

5.  Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.

Authors:  Michael F Egan; Richard E Straub; Terry E Goldberg; Imtiaz Yakub; Joseph H Callicott; Ahmad R Hariri; Venkata S Mattay; Alessandro Bertolino; Thomas M Hyde; Cynthia Shannon-Weickert; Mayada Akil; Jeremy Crook; Radha Krishna Vakkalanka; Rishi Balkissoon; Richard A Gibbs; Joel E Kleinman; Daniel R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

6.  Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats.

Authors:  Nurith Amitai; Athina Markou
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

7.  Dysfunctional connectivity in schizophrenia.

Authors:  Karl J Friston
Journal:  World Psychiatry       Date:  2002-06       Impact factor: 49.548

Review 8.  Imaging genomics and response to treatment with antipsychotics in schizophrenia.

Authors:  Giuseppe Blasi; Alessandro Bertolino
Journal:  NeuroRx       Date:  2006-01

9.  Functional reactivity of the dopaminergic system following acute and chronic ketamine treatments.

Authors:  A R Owolabi; M A Akanmu; O E Ukponmwan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-12       Impact factor: 3.000

10.  Effect of antipsychotic drugs on the gene expression of NMDA receptor subunits in rats.

Authors:  H Toyoda; R Takahata; Y Inayama; J Sakai; H Matsumura; H Yoneda; H Asaba; T Sakai
Journal:  Neurochem Res       Date:  1997-03       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.